Development and validation of a noninvasive prediction model for nonalcoholic steatohepatitis resolution after lifestyle intervention
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Liver biopsy is the gold standard method to assess nonalcoholic steatohepatitis (NASH) resolution after therapeutic interventions. We developed and validated a simple and noninvasive scoring system to predict NASH resolution without fibrosis worsening after 1 year of lifestyle intervention. This was a prospective cohort study conducted in 261 patients with histologically proven NASH who were treated with lifestyle changes for 52 weeks and underwent a second liver biopsy to confirm NASH resolution. We divided the data into development (140 subjects) and validation (121 individuals) sets. NASH resolution occurred in 28% (derivation group) and 27% (validation group). At the multivariable analysis, weight loss (odds ratio [OR] = 2.75, 95% confidence interval [CI] 1.65‐4.58; P < 0.01), type 2 diabetes (OR = 0.04, 95% CI 0.005‐0.49; P = 0.01), normal levels of alanine aminotransferase at the end of intervention (OR = 9.84, 95% CI 2.21‐44.1; P < 0.01), age (OR = 0.89, 95% CI 0.83‐0.97; P = 0.01), and a nonalcoholic fatty liver activity score ≥5 (OR = 0.08, 95% CI 0.01‐0.43; P < 0.01) were independent predictors of NASH resolution. The area under the receiver operating characteristic curve of the selected model was 0.956 and 0.945 in the derivation and validation cohorts, respectively. Using a score threshold of ≤46.15, negative predictive values were 92% in the derivation and validation groups, respectively. By applying a cutoff ≥69.72, positive predictive values were 92% and 89% in the derivation and validation groups, respectively. Using both cutoffs, a liver biopsy would have been avoided in 229 (88%) of 261 patients, with a correct prediction in 209 (91%) Conclusions: A noninvasive prediction model including weight loss, type 2 diabetes, alanine aminotransferase normalization, age, and a nonalcoholic fatty liver activity score ≥5 may be useful to identify NASH resolution in patients under lifestyle intervention. (H epatology 2016;63:1875‐1887)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · cited 4×
“c-Glutamyltransferase (U/L) 39 (26-63) 39 (26-58) 40 (27-64)”
BackgroundInfluentialBush, K. (1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.16.1789 · Cited by 6,196
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327 · cited 4×
“c-Glutamyltransferase (U/L) 39 (26-63) 39 (26-58) 40 (27-64)”
BackgroundInfluentialAngulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study
Adams, L. A., Lymp, J. F., St. Sauver, J., Sanderson, S. O., Lindor, K. D., Feldstein, A., & Angulo, P. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.04.014 · Cited by 2,890 · cited 1×
“Nonalcoholic fatty liver disease (NAFLD) has emerged as a leading cause of chronic liver disease,((1)) with a prevalence from 2.”
BackgroundVilar-Gomez, E., Martinez-Perez, Y., Calzadilla-Bertot, L., Torres-Gonzalez, A., Gra-Oramas, B., Gonzalez-Fabian, L., Friedman, S. L., Diago, M., & Romero-Gomez, M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.005 · Cited by 2,492
Self-citationLong-term follow-up of patients with NAFLD and elevated liver enzymes
Ekstedt, M., Franzén, L. E., Mathiesen, U. L., Thorelius, L., Holmqvist, M., Bodemar, G., & Kechagias, S. (2006) · Hepatology · doi:10.1002/hep.21327 · Cited by 2,302 · cited 2×
“Portal tracts (n) 14 (11-17) 13 (10-16) 15 (12-19) NAS 5 (4-6) 5 (4-6) 5 (4-6)”
BackgroundNeuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237 · cited 2×
“Portal tracts (n) 14 (11-17) 13 (10-16) 15 (12-19) NAS 5 (4-6) 5 (4-6) 5 (4-6)”
BackgroundPrognosis Research Strategy (PROGRESS) 3: Prognostic Model Research
Steyerberg, E. W., Moons, K. G. M., van der Windt, D. A., Hayden, J. A., Perel, P., Schroter, S., Riley, R. D., Hemingway, H., Altman, D. G., & for the PROGRESS Group (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001381 · Cited by 1,508 · cited 3×
“c-Glutamyltransferase (U/L) 39 (26-63) 39 (26-58) 40 (27-64)”
MethodUpdated definitions of healthy ranges for serum alanine aminotransferase levels
Prati, D., Taioli, E., Zanella, A., Torre, E. D., Butelli, S., Del Vecchio, E., Vianello, L., Zanuso, F., Mozzi, F., Milani, S., et al. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-1-200207020-00006 · Cited by 1,445 · cited 5×
“At baseline, all patients had ALT values higher than the upper normal limit based on genderspecific thresholds (>30 U/L for men and >19 U/L for women).((30)) No significant difference in WL (percentage) and changes in the physical activity score were observed between the two patient cohorts (see Supporting Table S1).”
BackgroundResultInfluential
Research works printed but not linked: 31
- 2008, The epidemiology of nonalcoholic fatty liver disease: a global perspective, Semin Liver Dis, 28, 339, 10.1055/s-0028-1091978 · DOI · Paper page
- 2011, Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults, Aliment Pharmacol Ther, 34, 274, 10.1111/j.1365-2036.2011.04724.x · DOI · Paper page
- 2013, The global NAFLD epidemic, Nat Rev Gastroenterol Hepatol, 10, 686, 10.1038/nrgastro.2013.171 · DOI · Paper page
- 2004, Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies, Hepatology, 40, 820
- 2011, Meta‐analysis: natural history of non‐alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non‐invasive tests for liver disease severity, Ann Med, 43, 617, 10.3109/07853890.2010.518623 · DOI · Paper page
- 2011, Endpoints and clinical trial design for nonalcoholic steatohepatitis, Hepatology, 54, 344, 10.1002/hep.24376 · DOI · Paper page
- 2012, The diagnosis and management of non‐alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association, Hepatology, 55, 2005, 10.1002/hep.25762 · DOI · Paper page
- 2010, A meta‐analysis of randomized trials for the treatment of nonalcoholic fatty liver disease, Hepatology, 52, 79, 10.1002/hep.23623 · DOI · Paper page
- 2014, GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes, Expert Opin Investig Drugs, 23, 1441, 10.1517/13543784.2014.954034 · DOI
- 2013, Dual peroxisome proliferator‐activated receptor alpha/delta agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects, Diabetes Care, 36, 2923, 10.2337/dc12-2012 · DOI · Paper page
- 2014, The fatty acid‐bile acid conjugate aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease, Clin Gastroenterol Hepatol, 12, 2085, 10.1016/j.cgh.2014.04.038 · DOI · Paper page
- 2003, Is weight reduction an effective therapy for nonalcoholic fatty liver? A systematic review, Am J Med, 115, 554, 10.1016/S0002-9343(03)00449-2 · DOI
- 2012, Exercise and non‐alcoholic fatty liver disease: a systematic review and meta‐analysis, J Hepatol, 57, 157, 10.1016/j.jhep.2012.02.023 · DOI · Paper page
- 2013, Prospective histopathologic evaluation of lifestyle modification in nonalcoholic fatty liver disease: a randomized trial, Therap Adv Gastroenterol, 6, 249, 10.1177/1756283X13484078 · DOI · Paper page
- 2015, Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases‐U.S. Food and Drug Administration Joint Workshop, Hepatology, 61, 1392, 10.1002/hep.27678 · DOI · Paper page
- 2009, Liver biopsy, Hepatology, 49, 1017, 10.1002/hep.22742 · DOI · Paper page
- 2005, Design and validation of a histological scoring system for nonalcoholic fatty liver disease, Hepatology, 41, 1313, 10.1002/hep.20701 · DOI · Paper page
- 2005, Validation of the AUDIT test for identifying risk consumption and alcohol use disorders in women. [in Spanish], Aten Primaria, 36, 499
- 2002, Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report, Circulation, 106, 3143, 10.1161/circ.106.25.3143 · DOI · Paper page
- 2009, Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD‐clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network, Hepatology, 49, 809, 10.1002/hep.22724 · DOI · Paper page
- 1996, Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors, Stat Med, 15, 361, 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4 · doi:10.1002/(sici)1097-0258(19960229)15:4<361::aid-sim168>3.0.co;2-4
- 2007, Benefits of lifestyle modification in NAFLD, Gut, 56, 1760, 10.1136/gut.2006.112094 · DOI · Paper page
- 2008, Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program, Diabetes Care, 31, 1416, 10.2337/dc07-2390 · DOI · Paper page
- 2012, Exercise training improves hemodynamic recovery to isometric exercise in obese men with type 2 diabetes but not in obese women, Metabolism, 61, 1739, 10.1016/j.metabol.2012.07.014 · DOI
- 2007, The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD, Hepatology, 45, 846, 10.1002/hep.21496 · DOI · Paper page
- 2008, Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease, Gut, 57, 1441, 10.1136/gut.2007.146019 · DOI · Paper page
- 2005, The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies, J Hepatol, 42, 132, 10.1016/j.jhep.2004.09.012 · DOI · Paper page
- 2006, Non‐invasive markers associated with liver fibrosis in non‐alcoholic fatty liver disease, Gut, 55, 1650, 10.1136/gut.2006.091454 · DOI · Paper page
- 2008, Behavior therapy for nonalcoholic fatty liver disease: the need for a multidisciplinary approach, Hepatology, 47, 746, 10.1002/hep.22009 · DOI · Paper page
- 2013, NAFLD: predictive value of ALT levels for NASH and advanced fibrosis, Nat Rev Gastroenterol Hepatol, 10, 510, 10.1038/nrgastro.2013.138 · DOI
- 2013, Predictive value of ALT levels for non‐alcoholic steatohepatitis (NASH) and advanced fibrosis in non‐alcoholic fatty liver disease (NAFLD), Liver Int, 33, 1398, 10.1111/liv.12226 · DOI · Paper page
Cited by
Treatment of NAFLD with diet, physical activity and exercise
Romero-Gómez, M., Zelber-Sagi, S., & Trenell, M. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.05.016 · Cited by 1,347
Self-citationCusi, K., Isaacs, S., Barb, D., Basu, R., Caprio, S., Garvey, W. T., Kashyap, S., Mechanick, J. I., Mouzaki, M., Nadolsky, K., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.03.010 · Cited by 1,021
Current and future pharmacological therapies for NAFLD/NASH
Sumida, Y., & Yoneda, M. (2018) · Journal of Gastroenterology · doi:10.1007/s00535-017-1415-1 · Cited by 667
Vilar-Gomez, E., & Chalasani, N. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.11.013 · Cited by 610
Self-citationDeterminants of Fibrosis Progression and Regression in NASH
Schuppan, D., Surabattula, R., & Wang, X. Y. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.11.012 · Cited by 479
“Based on these data, the authors developed an index, based on age, preintervention type 2 diabetes and NAS-score ≥5, weight loss and ALT normalization, with a high predictive value for NASH resolution (area under receiver operator curve <5) (27).”
Method
Metadata
- Authors
- Vilar‐Gomez, E., Yasells‐Garcia, A., Martinez‐Perez, Y., Calzadilla‐Bertot, L., Torres‐Gonzalez, A., Gra‐Oramas, B., Gonzalez‐Fabian, L., Villa‐Jimenez, O., Friedman, S. L., Diago, M., & Romero‐Gomez, M.
- Venue
- Hepatology
- Published
- 2016-03-10
- Volume
- 63
- Issue
- 6
- Pages
- 1875-1887
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W2293932895
- Cited by
- 59
- References
- 16
- FWCI
- 7.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- doi.wiley.com/10.1002/tdm_license_1.1 (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Development and validation of a noninvasive prediction model for nonalcoholic steatohepatitis resolution after lifestyle intervention. https://app.cochat.ai/papers/10.1002/hep.28484
- The paper
- Vilar‐Gomez, E., Yasells‐Garcia, A., Martinez‐Perez, Y., Calzadilla‐Bertot, L., Torres‐Gonzalez, A., Gra‐Oramas, B., Gonzalez‐Fabian, L., Villa‐Jimenez, O., Friedman, S. L., Diago, M., & Romero‐Gomez, M. (2016). Development and validation of a noninvasive prediction model for nonalcoholic steatohepatitis resolution after lifestyle intervention. Hepatology. https://doi.org/10.1002/hep.28484
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.